jakedogman1 wrote: "Where's Carl Icahn when you need him?"
I'm going to contact Mark H. Rachesky, M.D. and suggest he take a look at PPHM. He did cancer work before joining Carl Icahn and becoming a billionaire. He has investments in several companies, including biotechs: http://www.sec.gov/Archives/edgar/data/1277742/000101143807000450/mhrfund_13f-063007.txt He's going to be my write-in candidate instead of Swartz.
terrygd wrote: "Remember Oncolym? Beat the socks off SOC and now gone."
Did it beat the standard of care? If so, what happened? Why was it abandoned?
Why can't management do something smart like license bavituximab for veterinary use in the U.S.?
westjtter wrote: "the share price will eventually take care of itself."
Sure; even if it goes to zero, that's taking care of itself.
Some investors have bought and have then lost half their money. Management hasn't lost anything. They've gained: free shares and big salaries. They don't really care if PPHM goes to 0.01; they can then award themselves a billion shares. With nothing invested now, they really don't care about the share price, and they don't care anything about us. I'm really surprised they are only seeking authorization of 75 million shares now; I really think they may as well ask for a billion. 75 million shares x 0.25 (which is probably what they'll get after the "investors" short it down ahead of time and the underwriter gets his cut, etc.) is only $18.75 million. Then they'll need to ask for 150 million shares, etc. Why not just go for one billion now? Go for two or three billion.
They've known this was a development stage company, and instead of issuing more shares when the price was high, they just issue shares every 9 or 12 months, at lower and lower prices/share.
News 
Market Data 
Discover 
